2015
Prospective assessment of the decision-making impact of the Breast Cancer Index in recommending extended adjuvant endocrine therapy for patients with early-stage ER-positive breast cancer
Sanft T, Aktas B, Schroeder B, Bossuyt V, DiGiovanna M, Abu-Khalaf M, Chung G, Silber A, Hofstatter E, Mougalian S, Epstein L, Hatzis C, Schnabel C, Pusztai L. Prospective assessment of the decision-making impact of the Breast Cancer Index in recommending extended adjuvant endocrine therapy for patients with early-stage ER-positive breast cancer. Breast Cancer Research And Treatment 2015, 154: 533-541. PMID: 26578401, PMCID: PMC4661200, DOI: 10.1007/s10549-015-3631-9.Peer-Reviewed Original ResearchMeSH KeywordsAgedAged, 80 and overAntineoplastic Agents, HormonalAnxietyBreast NeoplasmsChemotherapy, AdjuvantDecision MakingFemaleGene Expression Regulation, NeoplasticGenetic TestingHumansMiddle AgedNeoplasm Recurrence, LocalPrognosisProspective StudiesReceptors, EstrogenSurveys and QuestionnairesTamoxifenConceptsBreast Cancer IndexExtended endocrine therapyER-positive breast cancerAdjuvant endocrine therapyEndocrine therapyDecisional Conflict ScaleBreast cancerCancer indexPhysician recommendationRisk/benefit discussionEarly-stage estrogen receptorEndocrine therapy trialsYale Cancer CenterPositive breast cancerState-Trait Anxiety Inventory FormMean STAIExtended therapyLate recurrenceAbsolute benefitCancer CenterPatient satisfactionPrognostic informationTreatment recommendationsPatient anxietyImproved outcomes
2004
Changes in plasma levels of inflammatory cytokines in response to paclitaxel chemotherapy
Pusztai L, Mendoza TR, Reuben JM, Martinez MM, Willey JS, Lara J, Syed A, Fritsche HA, Bruera E, Booser D, Valero V, Arun B, Ibrahim N, Rivera E, Royce M, Cleeland CS, Hortobagyi GN. Changes in plasma levels of inflammatory cytokines in response to paclitaxel chemotherapy. Cytokine 2004, 25: 94-102. PMID: 14698135, DOI: 10.1016/j.cyto.2003.10.004.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAntineoplastic AgentsAntineoplastic Combined Chemotherapy ProtocolsAnxietyBloodBreast NeoplasmsCyclophosphamideCytokinesData Interpretation, StatisticalDoxorubicinFatigueFemaleFluorouracilHumansInterleukin-1Interleukin-10Interleukin-12Interleukin-6Interleukin-8Middle AgedNauseaPaclitaxelPainPatient SelectionQuality of LifeTumor Necrosis Factor-alphaConceptsFlu-like symptomsIL-10 levelsIL-6IL-8IL-10Paclitaxel groupHealthy volunteersPaclitaxel chemotherapyJoint painIL-12Inflammatory cytokinesPlasma levelsTNF-alphaDay 3Single-agent paclitaxelBaseline cytokine levelsIL-8 levelsTransient side effectsHigh-dose treatmentWeekly paclitaxelCytokine levelsFAC chemotherapyMusculoskeletal symptomsCancer patientsIL-1beta